ASCO GU 2025 | Dr. Philip Kwong: Precision Testing and Individualized Management in mCRPC

ASCO GU 2025 | Dr. Philip Kwong: Precision Testing and Individualized Management in mCRPC

The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was held in San Francisco, California, from February 13 to 15. It attracted top experts and scholars in the field of urology from around the world. At this conference, Oncology Frontier invited Dr. Philip Kwong from The University of Hong Kong to share his insights on precision testing and individualized management in metastatic castration-resistant prostate cancer (mCRPC). He believes that precision testing and continuous monitoring are crucial for optimizing treatment strategies for mCRPC, and he particularly emphasized the key role of genetic testing in assessing homologous recombination repair (HRR) status. His insights not only provide important guidance for clinical practice but also bring new perspectives to the individualized treatment of mCRPC.
Dr. Angela Jia: Rapid Development of Radioligand Therapy, Combined with Local Radiotherapy May Further Improve Survival in Prostate Cancer Patients

Dr. Angela Jia: Rapid Development of Radioligand Therapy, Combined with Local Radiotherapy May Further Improve Survival in Prostate Cancer Patients

Radioligand Therapy (RLT) is an innovative treatment modality in the field of prostate cancer, enriching the therapeutic options. With further research, the personalized application of RLT and its combination with other therapies will become an important direction for the future treatment of prostate cancer. Oncology Frontier invited Dr. Angela Jia, an expert in radiation oncology at the UH Seidman Cancer Center, to share her insights on the role and future potential of RLT and local radiotherapy in the treatment of prostate cancer.
Dr. Wei Zhang: Two Decades of Organ-Preserving Surgery for Low Rectal Cancer in China – Reflections and Future Directions| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee

Dr. Wei Zhang: Two Decades of Organ-Preserving Surgery for Low Rectal Cancer in China – Reflections and Future Directions| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee

At the 9th Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee, Dr. Wei Zhang from The First Affiliated Hospital of the Naval Medical University reviewed the 20-year progress in the treatment of low rectal cancer in China and outlined future directions in the field. His presentation highlighted major advancements in organ-preserving surgery, minimally invasive techniques, neoadjuvant therapy, and immunotherapy, showcasing how these innovations have transformed the clinical landscape for low rectal cancer treatment.
Dr. Zheng Lou: Integrating Traditional and Western Medicine to Overcome the Challenge of Anastomotic Leakage After Low Rectal Cancer Surgery| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee

Dr. Zheng Lou: Integrating Traditional and Western Medicine to Overcome the Challenge of Anastomotic Leakage After Low Rectal Cancer Surgery| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee

With changing dietary habits and the increasing adoption of colorectal cancer screening, the incidence of low rectal cancer is on the rise in China. In Shanghai alone, the annual growth rate is estimated at 4.2% to 4.6%, with 70% to 80% of rectal cancers classified as mid-to-low rectal tumors. Despite advancements in surgical techniques, anastomotic leakage remains a critical challenge, with an incidence ranging from 1.6% to 20%. The risk is particularly pronounced in patients who have undergone neoadjuvant chemoradiotherapy, leading to severe complications such as high mortality rates, serious infections, loss of anal function, and an increased risk of tumor recurrence.